A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immunosuppressive drugs. Sirolimus, a new immunosuppressive agent, has been successfully used for immune-suppression in kidney transplant recipients. Several studies have shown the potential role of sirolimus to inhibit progression of KS in kidney-transplant recipients. This report details a kidney-transplant recipient with cutaneous KS who had a complete remission in response to sirolimus therapy.
Yilmaz
Rahmi
R
Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey.
Akoglu
Hadim
H
Kirkpantur
Alper
A
Kilickap
Saadettin
S
Arici
Mustafa
M
Altun
Bulent
B
Aki
Tuncay
T
Erdem
Yunus
Y
Yasavul
Unal
U
Turgan
Cetin
C
D000328:Adult; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D020123:Sirolimus / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology
D007166:Immunosuppressive Agents; D020123:Sirolimus